Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1995-10-11
1999-01-12
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
A61K 9127
Patent
active
058583971
ABSTRACT:
Compositions and methods which are useful for the treatment of solid tumors in a host and which are also useful for increasing the therapeutic index of mitoxantrone in a host. The pharmaceutical compositions are liposomal formulations of mitoxantrone in which the liposomes comprise a mixture of cholesterol and a diacylphosphatidylcholine, preferably 1,2-sn-dimyristoyl-phosphatidylcholine.
REFERENCES:
patent: 4863739 (1989-09-01), Perez-Soler
patent: 4885172 (1989-12-01), Bally
patent: 5013556 (1991-05-01), Woodle
patent: 5043166 (1991-08-01), Barenholz
patent: 5059421 (1991-10-01), Loughrey
patent: 5171578 (1992-12-01), Bally
Schenkenberg, T.D., et al. (1986) "Mitoxantrone: A new anticancer drug with significant clinical activity", Annals of Internal Medicine, 105:67-81.
Sugarmann, S.M., et al. (1992) "Liposomes in the treatment of malignancy: a clinical perspective", Critical Reviews in Oncology/Hematology, 12:231-242.
Bally, M.B., et al. (1994) Cancer Chemother. Pharamacol., 34:137-146.
Gabizon, A.A., et al. (1988) Proc. Natl. Acad. Sci., 85:6949-6953.
Gabizon, A.A., et al. (1992) "Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes", Cancer Res., 52:891-896.
Ogihara-Umeda, I., et al. (1994) "Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin", Cancer Res., 54:463-896.
Uchiyama, K., et al. (1995) "Effects of the side and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors", Intl. J. of Pharm., 121:195-203.
Wu, N.Z. (1993) "Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue", Cancer Res., 53:3765-3770.
Mayer, L.D., et al. (1990) "Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients", Biochim. Biophys Acta, 1025:143-151.
Bally, M.B., et al. (1988) Liposomes as Drug Carriers, G. Gregoriadis (ed.), 841-853, John Wiler & Sons, Ltd. Chichester.
Mayer, L.D., et al. (1989) "Influence of vesicle size, lipid composition and drug to lipid ratio on the biological activity of liposomal doxorubicin in mice", Cancer Res. 49:5922-5930.
Boman, N.L., et al. (1993) "Optimization of the retention properties of vincristine in liposomal vincristine", Biochim. Biophys. Acta, 1152:253-258.
Mayer, L.D., et al. (1985) "Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential", Biochim. Biophys. Acta, 816:294-302.
Parr, et al. (1994) Biochim. Biophys. Acta, 1195:21-30.
Madden, T.D., et al. (1990) "The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey", Chemistry and Physics of Lipids, 53:37-46.
Chonn, A., et al. (1991) Biochem. Biophys. Acta, 1070:215-222.
Weiss, R.B. (1989) "Mitoxantrone: Its development and role in clinical practice", Oncology, 3:135-140.
Law, S.L., et al. (1991) "Characteristics of mitoxantrone loading on liposomes", International Journal of Pharmaceutics, 70:1-7.
Law, S.L., et al. (1994) "Release characteristics of mitoxantrone-containing liposomes", International Journal of Pharmaceutics, 103:81-85.
Law, S.L., et al. (1995) "Stability of mitoxantrone-containing liposomes", International Journal of Pharmaceutics, 116:87-93.
Schwendener, R.A., et al. (1991) "Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy", Cancer Chemother. Pharmacol. 27:429-439.
Ehninger, G., et al. (1990) "Pharmacokinetics and metabolism of mitoxantrone", Clin. Pharmacokinet., 18:365-380.
Pestalozzi, B., et al. (1992) "Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer", Annals of Oncology, 3:445-449.
Beck, P., et al. (1993) "Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models", J. Microencapsulation, 10(1):101-114.
Genne, P., et al. (1994) "Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice", Anti Cancer Drug Design, 95:74-85.
Bonadonna, G., et al. (1992) "Current state of liposome-complexed drugs in the treatment of cancer patients", Annals of Oncology, 3:419-421.
Wolfe, J. J., et al, (1994) "Electrode potentials for bioreductive agents for neural network", Anti-Cancer Drug Design, 9:85-102.
Bally Marcel B.
Barber Lana W.
Chang Charmaine W.
Lim Howard J.
Madden Thomas D.
Kishore Gollamudi S.
University of British Columbia
LandOfFree
Liposomal formulations of mitoxantrone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal formulations of mitoxantrone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal formulations of mitoxantrone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512302